Although primarily recognized for its role in hemostasis, fibrinogen is also required for competent inflammatory reactions in vivo. It is now shown that fibrinogen promotes adhesion to and migration across an endothelial monolayer of terminally differentiated myelomonocytic cells.
ICAM-1. This interaction could also be inhibited by new anti-ICAM-1 monoclonal antibodies that did not affect the ICAM-1-CD11a/CD18 recognition, thus suggesting that the fibrinogen binding site on ICAM-1 may be structurally distinct from regions previously implicated in leukocyteendothelium interaction. Therefore, binding of fibrinogen to vascular cell receptors is sufficient to initiate (i) increased leukocyte adhesion to endothelium and (ii) leukocyte transendothelial migration. These two processes are the earliest events of immune inflammatory responses and may also contribute to atherosclerosis.
Fibrinogen plays a crucial role in primary hemostasis and platelet function, as highlighted by the bleeding disorders of afibrinogenemic individuals (1) . However, fibrinogen is also required for efficient inflammatory responses in vivo, as originally recognized during delayed-type hypersensitivity (2) . More recent studies have demonstrated that defibrinated animals fail to accumulate an inflammatory cell infiltrate after intraabdominal purulent challenges (3) , or at the site of biomaterial implant (4) , and that such animals are protected from glomerular lesions during the acute phase of immune-complex nephrotoxic nephritis (5) . The molecular mechanisms underlying fibrinogen-dependent inflammatory responses are poorly understood. Although fibrinogen fragments generated upon blood activation of coagulation exert chemotactic (6) and immunosuppressive effects (7), a role for the intact fibrinogen molecule in vascular injury and inflammation has been postulated as well.
General inflammatory responses and tissue-specific immune effector functions begin with a regulated "cascade" of adhesive interactions between leukocytes and vascular endothelium, followed by leukocyte extravascular migration across
The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. the endothelial cell monolayer (8, 9) . In a previous study, we have shown that fibrinogen and normal human plasma enhance the attachment of leukocytes to endothelium by acting as a molecular bridge between the two cell types (10) . The endothelial cell fibrinogen receptor mediating this bridging pathway with leukocytes was identified as intercellular adhesion molecule 1 (ICAM-1) (10) .
In this study, we show that the fibrinogen-ICAM-1 interaction can also mediate transendothelial migration of leukocytes and identify the sequence in fibrinogen that serves as a binding site for ICAM-1. We also show that fibrinogen binds to a site on ICAM-1 that is spatially distinct from that implicated in the recognition of CD11a/CD18 (9) .
MATERIALS AND METHODS
Cells and Cell Cultures. Peripheral blood mononuclear cells (PBMCs) and polymorphonuclear leukocytes (PMNs) were isolated from heparinized blood drawn after informed consent from normal healthy volunteers by differential centrifugation on Ficoll/Hypaque gradient and dextran sedimentation as described (11) . The promyelocytic cell line HL-60 was terminally differentiated to a monocyte-like phenotype by a 4-to 5-day culture in the presence of 0.1 ,uM 1,25-dihydroxyvitamin D3 (Biomol, Plymouth Meeting, PA) and indomethacin (17.8 ,ug/ml) (Calbiochem) according to published protocols (12) .
Previous studies have demonstrated that vitamin D3-differentiated HL-60 cells constitute a reliable model for in vitro monocyte function (13) . Human umbilical vein endothelial cells (HUVECs) were prepared by collagenase treatment (14) , or purchased from Clonetics (San Diego), and maintained in culture according to the supplier's specifications. For most experiments, HUVECs were used between passages 2 and 5. The integrity of the endothelial cell monolayer was confirmed before each experiment of leukocyte adhesion and transendothelial migration by phase-contrast microscopy and crystal violet staining.
Proteins and Synthetic Peptides. Human fibronectin and fibronectin-depleted fibrinogen were purified according to published protocols (11, 15 wild-type CHO cells and measurement of specific cell adhesion in the absence of fibrinogen after a 30-min incubation at 22°C was as described (10) .
RESULTS
Regulation of Leukocyte-Endothelium Interaction by Plasma Adhesive Proteins. Previous studies have demonstrated that fibrinogen enhances leukocyte adhesion to endothelium by acting as a molecular bridge between the two cell types (10) . The possible participation in this mechanism of additional plasma proteins with cell adhesion-promoting properties-i.e., vitronectin and fibronectin-was investigated.
While no specific adhesion of undifferentiated HL-60 promyelocytes to resting HUVEC monolayers was observed in the presence of soluble adhesive proteins (data not shown), fibrinogen or vitronectin enhanced by 3-to 4-fold the adhesion of vitamin D3-differentiated monocyte-like HL-60 cells (12, 13) or PBMCs to resting endothelium ( Fig. 1; data tions, despite the ability of differentiated HL-60 cells to strongly adhere to fibronectin substrate ( Fig. 1 ; data not shown). As shown in Fig. 1 , vitronectin enhanced monocytic HL-60 cell adhesion to HUVECs in a time-and dosedependent reaction ( Fig. 1 B and C) , approaching saturation at 50 ,ug/ml, in the range of the physiologic plasma concentrations of vitronectin (Fig. 1C) . These results are in agreement with a recent study showing that vitronectin specifically binds to the luminal side of endothelial cells (16) . Vitronectin did not further increase adhesion of differentiated HL-60 cells to TNF-a-stimulated HUVECs, as compared with control incubation reactions in the presence of transferrin (data not shown).
Effect of Plasma Adhesive Proteins on Leukocyte Transendothelial Migration. Tight adhesion of leukocytes to endothelium is followed by leukocyte transendothelial migration and tissuespecific homing (9, 17) . The possibility that plasma adhesive proteins mediating leukocyte-endothelium bridging might also direct leukocyte migration across the endothelium monolayer was investigated. As shown in Fig. 2 , in the absence of adhesive proteins or chemotactic gradients, PMNs or vitamin D3-differentiated HL-60 cells did not migrate across resting HUVEC monolayers, in agreement with previous observations (18) (Fig.  2) . In contrast, physiologic concentrations of fibrinogen or normal human plasma, but not vitronectin or serum, stimulated transendothelial migration of both cell types under the same experimental conditions (Fig. 2) . Similar results were obtained with PBMCs (data not shown). The effect of cytokine activation of HUVECs on leukocyte transmigration mediated by adhesive proteins was investigated. In agreement with previous observations (18, 19) , TNF-a-stimulated HUVECs supported transmigration of 3000 ± 1000 PMNs in the absence of adhesive proteins, as compared with the undetectable values observed for resting endothelium. Under these experimental conditions, fibrinogen promoted migration of 20,500 ± 500 PMNs through TNF-astimulated HUVECs, while, consistent with the data presented above, 4000 ± 1000 PMNs migrated through cytokine-activated HUVEC monolayers in the presence of vitronectin. Structural Requirements of Fibrinogen-Dependent Leukocyte Transendothelial Migration. The potential participation of ICAM-1 and of its recognition for fibrinogen (10) in leukocyte transendothelial migration was investigated in synthetic peptide and mAb inhibition studies. Survey of a large number of fibrinogen t-chain-derived synthetic peptides identified a peptide designated -y3 (N117NQKIVNLKEKVAQLEA133) that was capable of inhibiting leukocyte-endothelium interaction mediated by fibrinogen. The y3 peptide completely inhibited binding of 125I-fibrinogen to ICAM-1-expressing cells and specifically bound to ICAM-1 transfectants. Other fibrinogen y-chain-derived peptides, including peptides shown to bind to the aM(32 integrin (11), were not active under the same experimental conditions (unpublished observations). As shown in Fig. 3A, increasing (Fig. 3A) or a scrambled control peptide based on the y3 sequence (data not shown) were not inhibitory.
In parallel experiments, an anti-ICAM-1 mAb panel was generated by selecting for inhibition of binding of 125[_ fibrinogen to ICAM-1-expressing cells. One of these anti-ICAM-1 mAbs, 2D5, inhibited fibrinogen-mediated adhesion of PBMCs and vitamin D3-differentiated HL-60 cells to resting HUVEC monolayers to the background values observed in the presence of control protein transferrin ( Fig. 3B ; data not shown). Consistent with previous observations (10), saturating concentrations of anti-ICAM-1 mAb LB-2 inhibited by -50% the leukocyte-endothelium interaction, while control mAb 6A11 was ineffective (Fig. 3B) . In another series of experiments, saturating concentrations of mAb 2D5 failed to diminish HL-60 cell adhesion to monolayers of ICAM-1 transfectants in the absence of fibrinogen (Table 1 ). In contrast, anti-CD18 mAb 60.3, or the anti-ICAM-1 mAb 6E6, which does not affect fibrinogen recognition, completely inhibited HL-60 cell adhesion to ICAM-1 transfectants ( Table 1) .
The effect of these two classes of antagonists on fibrinogendependent leukocyte transendothelial migration was investigated. As shown in Fig. 4A , inhibitory concentrations of yy3 blocked transendothelial migration of vitamin D3-differentiated HL-60 cells mediated by fibrinogen or by autologous human plasma by 60-70%, respectively, while control peptide DIII (Kl62QSGLYFIKPLKAN175) was ineffective (Fig. 4A) . In parallel experiments, anti-ICAM-1 mAb 2D5 also inhibited by 50-75% fibrinogen-or plasma-dependent migration of vitamin D3-differentiated HL-60 cells across resting HUVEC monolayers (Fig. 4B) . In contrast, leukocyte preincubation with control mAb 6A11, or with anti-ICAM-1 mAb 6E6 (Table  1) , did not diminish leukocyte transendothelial migration mediated by fibrinogen or plasma (Fig. 4B) . DISCUSSION Soluble Adhesive Ligands Regulate Leukocyte-Endothelium Interaction and Leukocyte Transendothelial Migration. In this study, we have shown that the association of fibrinogen with vascular cells is sufficient to promote two among the earliest events of immune inflammatory responses: (i) increased adhesion of leukocytes to endothelium, and (ii) migration of leukocytes across the endothelial cell monolayer.
This adhesion pathway does not require chemotactic/ haptotactic gradients, or endothelial cell stimulation by inflammatory cytokines, and is ligand specific for fibrinogen since fibronectin was ineffective in mediating leukocyteendothelium interaction and both fibronectin and vitronectin failed to mediate transendothelial migration. Recent evidence accumulated with systemically defibrinated animals indicates that fibrinogen is absolutely required for inflammatory responses in vivo (3) (4) (5) . The ability of fibrinogen to act as a bridging molecule to enhance leukocyte attachment to endothelium (10, 20) , and to direct leukocyte transendothelial migration (this study), might provide a molecular basis for fibrinogen dependency of inflammatory responses in vivo. These observations have profound pathogenetic implications in the onset and progression of the atherosclerotic lesion, which is invariably characterized by increased attachment of leukocytes to endothelium followed by intraintimal leukocyte infiltration (21, 22) . This possibility is further highlighted by the large deposition of fibrin(ogen) on injured and atherosclerotic endothelium (23) and by the overexpression of ICAM-1 and other leukocyte adhesion-promoting molecules in all types of atherosclerotic lesions (24, 25) . Stimulation of ICAM-1 expression by locally generated thrombin (26) or by cytokines released by in situ macrophages (27) would further amplify this leukocyte adhesion cascade initiated by fibrinogen at the site of vascular injury.
Proc Natl. Acad Sci. USA 92 (1995) Structure-Function Relationship of ICAM-1-Fibrinogen Interaction. Based on synthetic peptidyl mimicry of the fibrinogen y chain, a peptide sequence designated ry3 (N117NQKIV-NLKEKVAQLEA133) was identified as responsible for leukocyte-endothelium bridging and transendothelial migration. This structural motif is partially contained within the epitope of the anti-fibrinogen mAb 9F9, which reacts with the conformationally rearranged molecule immobilized on plastic or bound to its platelet receptor (28) . Therefore, fibrinogenmediated leukocyte-endothelium bridging may occur through a sequential docking cascade, in which initial fibrinogen binding to leukocyte CD11b/CD18 (11) may result in spatial conformational changes (28) that render the y3 sequence more accessible for a secondary interaction with ICAM-1 (10) . This model would also be consistent with the ability of this pathway to mediate intercellular bridging in a physiologic plasma milieu (10) , containing large concentrations of soluble, competing fibrinogen. The topography of ICAM-1 recognition of fibrinogen was further dissected by generating a panel of anti-ICAM-1 mAbs. Functional characterization of these mAbs has demonstrated that inhibitors of fibrinogen-ICAM-1 interaction-i.e., mAb 2D5-did not affect ICAM-1 association with its counterreceptor CD11a/CD18, as demonstrated by HL-60 cell adhesion to monolayers of ICAM-1 transfectants. Conversely, the anti-ICAM-1 mAb 6E6, which completely inhibited ICAM-1-CD11a/CD18 interaction had no effect on recognition of fibrinogen. Based on these differential and mutually exclusive functional blocking properties, it seems plausible to hypothesize that the fibrinogen binding site on ICAM-1 may be spatially distinct from the complementary CD11a/CD18 recognition site, which also mediates leukocyte adhesion and transendothelial migration (8, 9, 17) . This suggests that the fibrinogen-dependent pathway of intercellular bridging may provide an additive and complementary mechanism to the general process of leukocyte-endothelium interaction (9) .
In summary, we have delineated a two-step pathway of cell adhesion and leukocyte locomotion mediated by fibrinogen and recapitulated by a physiologic plasma milieu that may contribute to various inflammatory responses in vivo. Current experiments performed under flow conditions and analysis of ICAM-1-fibrinogen antagonists-i.e., y3 and mAb 2D5-in animal models of inflammation should help elucidate the contribution of this pathway to the early molecular mechanisms of vascular injury in vivo.
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